Company: LHI
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006939
Chunk: 95

Company: Living Homeopathy International Ltd.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 95
---
 of $[●] per Class A Ordinary Share,            
 which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting 
 the estimated underwriting discounts and the estimated offering expenses payable by Living Homeopathy.                                     |

You should read this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and the information under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” beginning on page 55 of this prospectus.

|                                                                                                                                                                                                                                                                                                           |     |        |           |     | March 31, 2024 |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|----------:|:----|:---------------|
|                                                                                                                                                                                                                                                                                                           |     | Actual |           |     | Adjusted       |
|                                                                                                                                                                                                                                                                                                           |     | US$    |           |     | US$            |
| Shareholders’ equity:                                                                                                                                                                                                                                                                                     |     |        |           |     |                |
| Class A Ordinary Shares, US$0.001 par value, authorized 450,000,000 shares and 9,000,000 shares issued and outstanding on actual basis as of March 31, 2024; [●] shares issued and outstanding, as adjusted to reflect the 50,000,000 Class A Ordinary Shares issued and outstanding as of March 31, 2024 |     |        |       900 |     |                |
| Class B Ordinary Shares, US$0,001 par value, authorized 50,000,000 shares and 1,000,000 shares issued and outstanding as of March 31, 2024                                                                                                                                                                |     |        |           |     |                |
| Additional paid-in capital                                                                                                                                                                                                                                                                                |     |        |     1,282 |     |                |
| Retained earnings                                                                                                                                                                                                                                                                                         |     |        | 3,127,067 |     |                |
| Accumulated other comprehensive loss                                                                                                                                                                                                                                                                      |     |        |    30,766 |     |                |
| Total shareholders’ equity                                                                                                                                                                                                                                                                                |     |        | 3,098,583 |     |                |

<div align='center'>52

DILUTION</div>

If you invest in the Class A Ordinary Shares, your interest will be diluted for each Class A Ordinary Share you purchase to the extent of the difference between the initial public offering price per Class A Ordinary Share and Living Homeopathy’s net tangible book value per